A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease (MARITIME 3-J)
Latest Information Update: 10 Nov 2025
At a glance
- Drugs Maridebart cafraglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms MARITIME-3-J
- Sponsors Amgen
Most Recent Events
- 27 Jun 2025 Status changed from not yet recruiting to recruiting.
- 30 May 2025 New trial record